Home Newsfeeds Barclays Maintains Equal-Weight on SVB Finl Gr, Lowers Price Target to $638

Barclays Maintains Equal-Weight on SVB Finl Gr, Lowers Price Target to $638

Barclays analyst Jason Goldberg maintains SVB Finl Gr (NASDAQ:SIVB) with a Equal-Weight and lowers the price target from $789 to $638.

byBenzinga Newsdesk

July 25, 2022

1 minute read

Barclays analyst Jason Goldberg maintains SVB Finl Gr (NASDAQ:SIVB) with a Equal-Weight and lowers the price target from $789 to $638.

Morgan Stanley Maintains Equal-Weight on Liberty Broadband, Lowers Price Target to $122

By Benzinga Newsdesk

August 19, 9:15 AM

Morgan Stanley analyst Benjamin Swinburne maintains Liberty Broadband (NASDAQ:LBRDK) with a Equal-Weight and lowers the price target from $139 to $122.

LBRDK

Ra Medical System’s Electrophysiology Division Has Increased Demand For Its Non-Invasive Mapping System

By Happy Mohamed

July 24, 8:14 AM

New Hospitals Approve Use of VIVO and Existing Customers Increase Utilization FORT MILL, SC / ACCESSWIRE / July 24, 2023 / Ra Medical Systems, Inc. (NYSE/American:RMED) announced today that there is an increase in

RMED

The FDA Has Completed A Filing Review Of Valneva’s Biologics License Application For Its Single-shot Chikungunya Vaccine Candidate, VLA1553

By Benzinga Newsdesk

February 21, 5:10 AM

VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023.

VALN

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis

By Bill Haddad

July 11, 7:02 AM

Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla® Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

Barclays Maintains Equal-Weight on SVB Finl Gr, Lowers Price Target to $638

Related Posts

Morgan Stanley Maintains Equal-Weight on Liberty Broadband, Lowers Price Target to $122

Ra Medical System’s Electrophysiology Division Has Increased Demand For Its Non-Invasive Mapping System

The FDA Has Completed A Filing Review Of Valneva’s Biologics License Application For Its Single-shot Chikungunya Vaccine Candidate, VLA1553

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis